|
|
Vol. 22.09 – 15 March, 2021
|
|
|
|
|
|
|
|
The authors demonstrated using an immune-competent mouse model of B cell acute lymphoblastic leukemia that Regnase-1 deficiency promoted TCF-1 expression to enhance CAR-T cell expansion and memory-like cell formation.
[Blood]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Transplantation of hematopoietic stem cells transduced with lentiviral vector expressing green florescent protein into lethally irradiated recipient mice was followed by intracranial implantation of glioblastoma cells.
[Journal For Immunotherapy of Cancer]
|
|
|
|
|
|
Scientists imaged 37 patients with stroke, 17 patients treated with mononuclear cells and 20 patients who received standard of care.
[STEM CELLS Translational Medicine]
|
|
|
|
|
|
Researchers genetically edited mesenchymal stem cells (MSCs) to overexpress bone morphogenetic protein 9 (BMP-9) using CRISPR-Cas9 to generate iMSCs-VPRBMP-9+, followed by in vitro evaluation of osteogenic potential and in vivo enhancement of bone formation in rat calvaria defects.
[Gene Therapy]
|
|
|
|
|
|
Scientists demonstrated the generation of AAV constructs carrying the human Complement Factor I (CFI) sequence and expression of CFI in cell lines and in the retina of C57BL/6 J mice.
[Gene Therapy]
|
|
|
|
|
|
Single cell RNA sequencing of neonatal human and mouse lung was used to identify the heterogeneity of pulmonary endothelial progenitor cells (EPCs). CRISPR/Cas9 gene editing was used to genetically label and purify mouse pulmonary EPCs.
[American Journal of Respiratory and Critical Care Medicine]
|
|
|
|
|
|
Researchers investigated such cell‐cell interaction between mesenchymal stem cells (MSCs) and cerebral endothelial cells. In contrast to bone marrow mononuclear cells, for MSCs they observed suppression of vascular endothelial growth factor uptake into endothelial cells and transfer of glucose from endothelial cells to MSC in vitro.
[Stem Cells]
|
|
|
|
|
|
Investigators developed a bioprinting strategy to engineer prevascularised tissues in vitro and to investigate the capacity of such constructs to enhance the vascularisation and regeneration of large bone defects in vivo.
[Acta Biomaterialia]
|
|
|
|
|
|
The authors established conditionally immortalized myeloid progenitor cell lines co-expressing constitutive Hoxa9.EGFP and inducible Meis1.dTomato to study growth behavior, immunophenotype and morphology under different cytokine/microenvironmental conditions ex vivo upon doxycycline induction or removal. [Scientific Reports]
|
|
|
|
|
|
Researchers describe a novel strategy for establishing a zebrafish model for drug testing in leukemia xenografts. They used chronic myelogenous leukemia and acute myeloid leukemia for xenotransplantation into severe combined immunodeficiency zebrafish to evaluate drug screening protocols.
[Scientific Reports]
|
|
|
|
|
|
|
|
Improvements in clinical applications of genetic and measurable residual disease information as well as in transplantation technology are expected to further refine indications for allogeneic hematopoietic cell transplantation during first complete remission.
[Bone Marrow Transplantation]
|
|
|
|
|
|
The authors summarize the current state of knowledge on immune mechanisms of gastric cancer and the status of emerging immunotherapies to treat this aggressive cancer, as well as outline current challenges and directions for future research.
[Cancer Gene Therapy]
|
|
|
|
|
|
Scientists review and summarize the latest studies about CRISPR/Cas9-mediated genome editing in patient-derived HSPCs and iPSCs to treat hereditary hematological disorders.
[Gene Therapy]
|
|
|
|
|
|
|
|
HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like cells differentiated from adipose tissue-derived stromal cells using Namocell’s Single Cell Dispensers and Takara Bio’s SMART-seq® kits to characterize HepaTx’s novel cell therapies for liver disease.
[HepaTx Corporation (PR Newswire Inc.)]
|
|
|
|
|
|
The Schulich School of Engineering, under Dr. Michael Kallos, a professor in the Department of Chemical and Petroleum Engineering, and director of the Biomedical Engineering Calgary Initiative, has been developing technologies to safely and reproducibly grow stem cells- whether they be skin cells, neural cells, or cells in any other part of the body.
[University of Calgary]
|
|
|
|
|
|
|
|
March 22 – 24, 2021
Virtual
|
|
|
|
|
|
|
|
|
|
|
The University of Iowa – Iowa City, Iowa, United States
|
|
|
|
|
|
|
Gladstone Institute – San Francisco, California, United States
|
|
|
|
|
|
|
National University of Ireland Galway – Galway, Ireland
|
|
|
|
|
|
|
Dana-Farber Cancer Institute – Boston, Massachusetts, United States
|
|
|
|
|
|
|
Children’s Hospital of Philadelphia – Philadelphia, Pennsylvania, United States
|
|
|
|
|
|